How Precision Immunology Is Transforming Rheumatology Drug Development
As understanding of autoimmune disease biology advances, rheumatology drug development is moving beyond broad immunosuppression toward targeted strategies tailored to disease mechanisms and patient populations.
In this Q&A with Citeline, Dr. Mila Grieg, Vice President, Medical Affairs & ACE Strategy Head, Immunology & Inflammation, discusses what precision immunology means for clinical development today. From biomarker-driven enrichment to recruitment, clinical trial operations, and regulatory planning, she explores key opportunities and challenges for sponsors.
The article explores:
- What is driving the shift from broad immunosuppression toward targeted approaches in rheumatology
- How biologically defined patient populations and enrichment strategies are reshaping trial design
- Challenges in biomarker validation, recruitment, site selection, and trial execution
- How biomarkers inform dose selection, proof-of-concept, go/no-go decisions, and regulatory planning
- Emerging technologies in precision immunology and why these strategies matter early in development
Request a Proposal
Share This
